Capricor and Praxis: what a three-month delay actually means

Haverhill Financial Research · News · October 11, 2026

Capricor's decision on deramiocel for Duchenne muscular dystrophy moved from August 22 to November 22. Praxis Precision Medicines' decision on relutrigine for two rare childhood epilepsies moved from September 27 to December 27. In both cases the FDA extended its review after the company sent in significant new information. Neither was a rejection.

Under the rules that set FDA review timelines, when a company submits a "major amendment" during a review, such as new analyses or a substantial change to the application, the agency can extend its goal date by three months to review it. The extension is a matter of time, not a judgment on the drug.

What matters is why the new information was needed. An extension prompted by a safety question or a manufacturing problem is a worse sign than one prompted by extra analyses of data the FDA already has.

Capricor narrowed what it is asking for. It now seeks approval based on upper-limb function in Duchenne, the main goal that its HOPE-3 trial met. A narrower request built around the trial's primary endpoint is easier to approve, though it may also mean a narrower label.

Praxis said the extension followed additional analyses it submitted, and that the FDA had not raised any safety or manufacturing issues. That is the most reassuring version of an extension a company can report.

For Capricor, the exact label wording, since a label tied to upper-limb function defines who can be treated and how the drug is marketed. For Praxis, whether the label covers both SCN2A and SCN8A forms of the disease. Both dates are on our biotech calendar.

Delays sound bad and often are not. In these two cases the companies have told investors what changed: Praxis says no safety or manufacturing issues were raised, and Capricor has narrowed its request to the endpoint its trial met. The outcomes are still uncertain; the delays themselves tell us less than the headlines suggested.

Capricor Therapeutics press release of August 24, 2026 and quarterly filings; Praxis Precision Medicines press release of June 29, 2026 and quarterly filings.

Disclosures. Haverhill Financial Research is a publisher of general financial commentary. This article is not personalized investment advice and does not consider any reader's financial situation; readers should do their own research. Nothing here is a recommendation to buy or sell any security. Company figures and guidance can change. The author of this post does not hold positions in the companies named. Data as of October 11, 2026.